Mean change from baseline of outcome measures, and difference in scores between the placebo and indomethacin group, after six months and one year of treatment.

*differences, adjusted for baseline (analysis of covariance). Negative change in scores from baseline indicates improvement, with the exception of the MMSE score (positive change indicates improvement), and the CIBIC+ (higher score means worse compared to baseline). Positive difference between groups means in favor of the indomethacin group, for all measures. ADAS-cog = cognitive subscale of the Alzheimer's Disease Assessment Scale; ADAS-noncog = noncognitive subscale of the ADAS; MMSE = Mini-Mental State Examination; NPI = Neuropsychiatric Inventory; NPI-D = caregiver distress scale of the NPI; IDDD = Interview for Deterioration in Daily life in Dementia; CIBIC+ = Clinician's Interview Based Impression of Change with caregiver input.